胃复春联合铋剂四联疗法治疗萎缩性胃炎并Hp 感染临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R573.3+2

基金项目:


Clinical Study on Weifuchun Combined with Bismuth Quadruple Therapy for Atrophic Gastritis Complicated with Hp Infection
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察胃复春联合铋剂四联疗法治疗萎缩性胃炎并幽门螺杆菌(Hp) 感染的临床疗效及对 Hp 的根除效果。方法:选取80 例萎缩性胃炎并Hp 感染患者为研究对象,按随机数字表法分为观察组和对照 组各40 例。对照组采用铋剂四联疗法治疗,观察组采用胃复春联合铋剂四联疗法治疗。比较2 组临床疗效、 Hp 根除率、中医证候评分、炎症因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-4(IL-4)、白细胞介素-33(IL-33) ] 水平、生长因子[表皮细胞生长因子(EGF)、血管内皮细胞生长因子(VEGF) ]水平及不良反应发生情况。结 果:观察组总有效率为92.50%,对照组为75.00%,2 组比较,差异有统计学意义(P<0.05)。随访1 个月,观察 组Hp 根除率为95.00%,对照组为80.00%,2 组比较,差异有统计学意义(P<0.05)。治疗后,2 组中医证候 评分均较治疗前降低(P<0.05),且观察组中医证候评分低于对照组(P<0.05)。治疗后,2 组TNF-α、 IL-4、IL-33 水平均较治疗前降低(P<0.05),且观察组3 项指标均低于对照组(P<0.05)。治疗后,2 组 EGF 水平均较治疗前降低(P<0.05),VEGF 水平均较治疗前升高(P<0.05);且观察组EGF 水平低于对照 组(P<0.05),VEGF 水平高于对照组(P<0.05)。治疗期间,2 组患者均未出现严重不良反应。结论:胃复 春联合铋剂四联疗法可改善萎缩性胃炎并Hp 感染患者的临床症状,降低机体炎症反应水平,恢复内皮功能, Hp 根除效果良好。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Weifuchun combined with bismuth quadruple therapy on atrophic gastritis complicated with Helicobacter pylori (Hp) infection and its effect on Hp eradication. Methods:A total of 80 cases of patients with atrophic gastritis and Hp infection were selected as the study objects and divided into the observation group and the control group according to the random number table method,with 40 cases in each group. The control group was treated with bismuth quadruple therapy,and the observation group was treated with Weifuchun combined with bismuth quadruple therapy. The clinical effects,Hp eradication rates,traditional Chinese medicine (TCM) syndrome scores,levels of inflammatory factors [tumor necrosis factor (TNF-α),interleukin-4 (IL-4),and interleukin-33 (IL-33)] and growth factors [epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF)], and the incidence of adverse reactions were compared between the two groups. Results: The total effective rate was 92.50% in the observation group and 75.00% in the control group,the difference being significant (P< 0.05). After 1-month follow-up,the Hp eradication rate was 95.00% in the observation group and 80.00% in the control group,the difference being significant (P<0.05). After treatment,TCM syndrome scores in the two groups were decreased when compared with those before treatment (P<0.05), and TCM medicine syndrome score in the observation group was lower than that in the control group (P<0.05). After treatment,the levels of TNF-α,IL-4 and IL-33 in the two groups were decreased when compared with those before treatment (P<0.05),and the three indexes in the observation group were lower than those in the control group (P<0.05). After treatment,EGF levels in the two groups were decreased when compared with those before treatment (P<0.05),and VEGF levels were increased when compared with those before treatment (P<0.05);EGF level in the observation group was lower than that in the control group (P<0.05), and VEGF level was higher than that in the control group (P<0.05). During treatment,no serious adverse reaction occurred in the two groups. Conclusion:Weifuchun combined with bismuth quadruple therapy for patients with atrophic gastritis and Hp infection can improve their clinical symptoms, reduce the levels of inflammatory responses,and restore the endothelial function,with a good effect on Hp eradication.

    参考文献
    相似文献
    引证文献
引用本文

王浩,谢晓红,毕玉珍,于立.胃复春联合铋剂四联疗法治疗萎缩性胃炎并Hp 感染临床研究[J].新中医,2024,56(6):85-89

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-03-26
  • 出版日期:
文章二维码